Anti-A antibody (Anti-A)

Anti-A antibodies are naturally occurring isoagglutinins found in the plasma of individuals with blood type B or O, primarily functioning to recognize the A carbohydrate antigen on red blood cells (StatPearls, 2023). These antibodies are predominantly of the IgM isotype, which are highly efficient at activating the classical complement pathway, leading to intravascular hemolysis and potential systemic inflammatory responses (NCBI, 2022). In the context of ABO-incompatible organ transplantation, anti-A antibodies are significant therapeutic targets; their presence can lead to hyperacute rejection by binding to the vascular endothelium of the graft and triggering thrombosis (Journal of Clinical Apheresis, 2020). Clinical management of these antibodies involves the use of therapeutic apheresis, such as plasmapheresis or antigen-specific immunoadsorption, to physically remove them from the recipient's circulation prior to and after transplantation (PubMed, 2021). Additionally, pharmacological agents such as rituximab are employed to deplete the B-cell populations responsible for producing these antibodies, while intravenous immunoglobulin (IVIG) or enzymatic agents like imlifidase may be used to neutralize or cleave remaining circulating titers to ensure graft survival (Transplantation Reviews, 2019).

Other names

Anti-A isoagglutininBlood group A antibodyIsohemagglutinin anti-AABO1 antibody

Therapeutic strategies focus on the physical removal of circulating antibodies via plasmapheresis or selective immunoadsorption, enzymatic degradation of IgG antibodies, neutralization of existing antibodies using pooled immunoglobulins, or the pharmacological suppression of antibody-producing B cells and plasma cells.